8074 related articles for article (PubMed ID: 2254373)
1. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
[TBL] [Abstract][Full Text] [Related]
2. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development.
Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999
[TBL] [Abstract][Full Text] [Related]
3. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Hofs HP; Wagener DJ; De Vos D; Ottenheijm HC; Winkens HJ; Bovee PH; De Grip WJ
Eur J Cancer; 1995; 31A(9):1526-30. PubMed ID: 7577083
[TBL] [Abstract][Full Text] [Related]
4. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
Fodstad O; Aamdal S; Pihl A; Boyd MR
Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
6. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening.
Berger DP; Henss H; Winterhalter BR; Fiebig HH
Ann Oncol; 1990 Sep; 1(5):333-41. PubMed ID: 2261375
[TBL] [Abstract][Full Text] [Related]
7. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
Kjønniksen I; Breistøl K; Fodstad O
Cancer Res; 1992 Mar; 52(5):1347-51. PubMed ID: 1737396
[TBL] [Abstract][Full Text] [Related]
8. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
10. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow.
Berger DP; Winterhalter BR; Dengler WA; Fiebig HH
Anticancer Drugs; 1992 Oct; 3(5):531-9. PubMed ID: 1450448
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
12. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
Fairbairn LJ; Chinnasamy N; Lashford LS; Chinnasamy D; Rafferty JA
Cancer Gene Ther; 2000 Feb; 7(2):233-9. PubMed ID: 10770631
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
14. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221.
Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
Cancer Chemother Pharmacol; 1991; 28(5):351-6. PubMed ID: 1914078
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
20. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
